5′-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells

Journal of Cellular Physiology

Volumn 228, Issue 3, 2013, Pages 602-608

  Quezada, Claudia ^a   Garrido, Wallys ^a   Oyarzún, Carlos ^a   Fernández, Katia ^b   Segura, Rodrigo ^c   Melo, Rómulo ^c   Casanello, Paola ^d   Sobrevia, Luis ^d   San Martín, Rody ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^b UNIVERSIDAD DIEGO PORTALES   (Chile)

^c Instituto de Neurocirugia Dr Asenjo   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A3 RECEPTOR; ECTO 5' NUCLEOTIDASE; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA; VINCRISTINE; 5' NUCLEOTIDASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; RNA;

ARTICLE; CELL CULTURE; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; GLIA CELL; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; BRAIN TUMOR; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

5'-NUCLEOTIDASE; BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RECEPTOR, ADENOSINE A3; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VINCRISTINE;

EID: 84870424506     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24168     Document Type: Article

References (46)

1. Bavaresco L, Bernardi A, Braganhol E, Cappellari AR, Rockenbach L, Farias PF, Wink MR, Delgado-Cañedo A, Battastini AM. 2008. The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem 319:61-68.
2. Benyahia B, Huguet S, Declèves X, Mokhtari K, Crinière E, Bernaudin JF, Scherrmann JM, Delattre JY. 2004. Multidrug resistance-associated protein MRP1 expression in human gliomas: Chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neurooncol 66:65-70.
3. Bronger H, König J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler D, Nies AT. 2005. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 65:11419-11428.
4. Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, Boiardi A, Salmaggi A. 2005. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74:113-121.
5. Chang SM, Butowski NA, Sneed PK, Garner IV. 2006. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme. Neurosurg Focus 20:E4.
6. Clarke J, Butowski N, Chang S. 2010. Recent advances in therapy for glioblastoma. Arch Neurol 67:279-283.
7. de Faria GP, de Oliveira JA, de Oliveira JG, Romano Sde O, Neto VM, Maia RC. 2008. Differences in the expression pattern of P-glycoprotein and MRP1 in low-grade and high-grade gliomas. Cancer Invest 26:883-889.
8. Declèves X, Fajac A, Lehmann-Che J, Tardy M, Mercier C, Hurbain I, Laplanche JL, Bernaudin JF, Scherrmann JM. 2002. Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 98:173-180.
9. Declèves X, Amiel A, Delattre JY, Scherrmann JM. 2006. Role of ABC transporters in the chemoresistance of human gliomas. Curr Cancer Drug Targets 6:433-445.
10. Echevarria-Lima J, Kyle-Cezar F, Leite DF, Capella L, Capella MA, Rumjanek VM. 2005. Expression and activity of multidrug resistance protein 1 in a murine thymoma cell line. Immunology 114:468-475.
11. Fredholm B, IJzerman A, Jacobson K, Linden J, Müller CE. 2011. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-An update. Pharmacol Rev 63:1-34.
12. Garrido W, Muñoz M, San Martín R, Quezada C. 2011. FK506 confers chemosensitivity to anticancer drugs in glioblastoma multiforme cells by decreasing the expression of the multiple resistance-associated protein-1. Biochem Biophys Res Commun 411:62-68.
13. Gessi S, Sacchetto V, Fogli E, Merighi S, Varani K, Baraldi PG, Tabrizi MA, Leung E, Maclennan S, Borea PA. 2010. Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. Biochem Pharmacol 79:1483-1495.
14. Grobben B, Anciaux K, Roymans D, Stefan C, Bollen M, Esmans EL, Slegers H. 1999. An ecto-nucleotide pyrophosphatase is one of the main enzymes involved in the extracellular metabolism of ATP in rat C6 glioma. J Neurochem 72:826-834.
15. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. 2009. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8:3274-3284.
16. Jemal A, Siegel R, Xu J, Ward E. 2010. Cancer statistics 2010. Cancer J Clin 60:277-300.
17. Jensen RL. 2009. Brain tumor hypoxia: Tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92:317-335.
18. Lee H, Lin EC, Liu L, Smith JW. 2003. Gene expression profiling of tumor xenografts: In vivo analysis of organ-specific metastasis. Int J Cancer 107:528-534.
19. Leth-Larsen R, Lund R, Hansen HV, Laenkholm AV, Tarin D, Jensen ON, Ditzel HJ. 2009. Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics 8:1436-1449.
20. Li X, Zhou T, Zhi X, Zhao F, Yin L, Zhou P. 2006. Effect of hypoxia/reoxygenation on CD73 (ecto-5'-nucleotidase) in mouse microvessel endothelial cell lines. Microvasc Res 72:48-53.
21. Loscher W, Potschka H. 2005. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:591-602.
22. Lu C, Shervington A. 2008. Chemoresistance in gliomas. Mol Cell Biochem 12:71-80.
23. Ludwig HC, Rausch S, Schallock K, Markakis E. 1999. Expression of CD73 (ecto-5'-nucleotidase) in 165 glioblastomas by immunohistochemistry and electronmicroscopic histochemistry. Anticancer Res 19:1747-1752.
24. Matsumoto Y, Miyake K, Kunishio K, Tamiya T, Seigo N. 2004. Reduction of expression of the multidrug resistance protein (MRP)1 in glioma cells by antisense phosphorothioate oligonucleotides. J Med Invest 51:194-201.
25. Matsumoto Y, Tamiya T, Nagao S. 2005. Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2. J Med Invest 52:41-48.
26. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, MacLennan S, Baraldi PG, Borea PA. 2005. A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia 7:894-903.
27. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Borea PA. 2006. Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol 72:19-31.
28. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Baraldi PG, Borea PA. 2007a. Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol 72:162-172.
29. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, Borea PA. 2007b. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 72:395-406.
30. Morrone FB, Jacques-Silva MC, Horn AP, Bernardi A, Schwartsmann G, Rodnight R, Lenz G. 2003. Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines. J Neurooncol 64:211-218.
31. Ozben T. 2006. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 580:2903-2909.
32. Peigñan L, Garrido W, Segura R, Melo R, Rojas D, Cárcamo JG, San Martín R, Quezada C. 2011. Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro. Neurochem Res 36:1397-1406.
33. Quezada C, Garrido W, González-Oyarzún M, Rauch MC, Salas M, San Martín R, Claude AA, Yañez AJ, Slebe JC, Cárcamo JG. 2008. Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells. Biol Pharm Bull 31:1911-1916.
34. Quezada C, Peigñan L, Segura R, Riquelme F, Melo R, Rojas ZD, Ayach F, San Martín R, Cárcamo JG. 2011. Study of resistance to chemotherapy mediated by ABC transporters in biopsies of glioblastoma multiforme. Rev Med Chil 139:415-424.
35. Sadej R, Spychala J, Skladanowski AC. 2006. Ecto-5′-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells. Nucleosides Nucleotides Nucleic Acids 25:1119-1123.
36. Sharom FJ. 2008. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9:105-127.
37. Stagg J, Smyth MJ. 2010. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29:5346-5358.
38. Stagg J, Divisekeraa U, McLaughlina N, Sharkeya J, Pommeyb S, Denoyerd D, Dwyer KM, Smyth MJ. 2010. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. PNAS 107:1547-1552.
39. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ. 2011. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 71:2892-2900.
40. Stupp R, van den Bent MJ, Hegi ME. 2005. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5:198-206.
41. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP. 2002. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-induciblefactor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110:993-1002.
42. Taliani S, Pugliesi I, Bellandi M, La Motta C, Da Settimo F. 2010. A3 receptor ligands: Past, present and future trends. Curr Top Med Chem 10:942-975.
43. Ujhazy P, Berleth ES, Pietkiewicz JM, Kitano H, Skaar JR, Ehrke MJ, Mihich E. 1996. Evidence for the involvement of ecto-5′-nucleotidase (CD73) in drug resistance. Int J Cancer 68:493-500.
44. Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X, Yin L, Shao Z, Ou Z, Zhou P. 2008. Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 134:365-372.
45. Zhi X, Wang Y, Zhou X, Yu J, Jian R, Tang S, Yin L, Zhou P. 2010. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci 101:2561-2569.
46. Zhou X, Zhi X, Zhou P, Chen S, Zhao F, Shao Z, Ou Z, Yin L. 2007. Effects of ecto-5′- nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol Rep 17:1341-1346.